Science & Enterprise subscription

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Immunotherapy Biotech Raises $102 Million in IPO

A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering. . . . → Read More: Immunotherapy Biotech Raises $102 Million in IPO

Biopharm Company Raising $40 Million in IPO

Omeros Corporation, a biopharmaceutical company developing drugs that prevent inflammation in surgeries, is raising $40 million in its initial public stock offering. . . . → Read More: Biopharm Company Raising $40 Million in IPO

Immunotherapy Company Raises $70 Million in IPO

Selecta Biosciences, a biotechnology company developing treatments harnessing the immune system, is raising $70 million in its initial public offering. . . . → Read More: Immunotherapy Company Raises $70 Million in IPO

Genome-Editing Company Raises $108 Million in IPO

Artist depiction of Cas9 protein editing a gene (Jennifer Doudna, University of California – Berkeley)

6 May 2016. Intellia Therapeutics, a developer of therapies based on genome editing, issued its initial public stock offering, raising $108 million. The Cambridge, Massachusetts enterprise, less than 2 years old, issued 6 million shares priced at $18.00. At . . . → Read More: Genome-Editing Company Raises $108 Million in IPO

Cancer Diagnostics Company Raises $12.3M in IPO

(A. Kotok)

18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced at . . . → Read More: Cancer Diagnostics Company Raises $12.3M in IPO

Genome-Editing Company Raises $94 Million in IPO

(bfishadow, WikimediaCommons)

3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, . . . → Read More: Genome-Editing Company Raises $94 Million in IPO

Gene Therapy Company Raises $70 Million in IPO

(bfishadow, WikimediaCommons)

11 November 2015. Voyager Therapeutics, a company less that two years old developing gene therapies for central nervous system disorders is raising $70 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, trading on the Nasdaq exchange (symbol: VYGR), offered 5 million shares yesterday at $14.00. Shares closed today at . . . → Read More: Gene Therapy Company Raises $70 Million in IPO

RNA Therapy Biotech Earns $44 Million in IPO

(bfishadow, WikimediaCommons)

1 October 2015. A biotechnology company developing therapies based on RNA, genetic material that sends signals to cells, raised $43.75 million in its initial public stock offering. Mirna Therapeutics Inc. in Austin, Texas issued 6.25 million shares today at $7.00, and trades on the Nasdaq exchange under the symbol MIRN. Its shares . . . → Read More: RNA Therapy Biotech Earns $44 Million in IPO

Synthetic Biology Company Raises $200 Million in IPO

(A. Kotok)

21 August 2015. Intrexon Corp., a company developing genomic solutions with synthetic biology, raised some $200 million in its initial public stock offering. The Germantown, Maryland enterprise issued 4,878,049 shares of common stock priced at $41.00, and traded on the New York Stock Exchange under the symbol XON. The company’s shares closed . . . → Read More: Synthetic Biology Company Raises $200 Million in IPO

Blood Disease Biotech Gains $120 Million in IPO

Red blood cells with sickle cell disease (NCATS.NIH.gov)

12 August 2015. Global Blood Therapeutics, a biotechnology company developing treatments for blood-related disorders, is raising $120 million in its initial public stock offering. The company, in South San Francisco, California and trading on the Nasdaq exchange under the symbol GBT, issued 6 million shares priced . . . → Read More: Blood Disease Biotech Gains $120 Million in IPO